Arcturus Therapeutics Ltd. that it is extending its partnership with Takeda Pharmaceutical Company Limited. Under the collaboration, Takeda and Arcturus will advance their efforts to develop RNA-based therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and other gastrointestinal (GI) related disorders using Arcturus's wholly-owned LUNAR lipid-mediated delivery systems and UNA Oligomer chemistry.